130 related articles for article (PubMed ID: 31129344)
1. Development and characterization of nanobubbles containing paclitaxel and survivin inhibitor YM155 against lung cancer.
Başpınar Y; Erel-Akbaba G; Kotmakçı M; Akbaba H
Int J Pharm; 2019 Jul; 566():149-156. PubMed ID: 31129344
[TBL] [Abstract][Full Text] [Related]
2. Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.
Gholizadeh S; Dolman EM; Wieriks R; Sparidans RW; Hennink WE; Kok RJ
Pharm Res; 2018 Mar; 35(4):85. PubMed ID: 29516187
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Cellular Uptake and Gene Silencing Activity of Survivin-siRNA via Ultrasound-Mediated Nanobubbles in Lung Cancer Cells.
Akbaba H; Erel-Akbaba G; Kotmakçı M; Başpınar Y
Pharm Res; 2020 Aug; 37(8):165. PubMed ID: 32761250
[TBL] [Abstract][Full Text] [Related]
4. Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer.
Shimizu T; Nishio K; Sakai K; Okamoto I; Okamoto K; Takeda M; Morishita M; Nakagawa K
Cancer Chemother Pharmacol; 2020 Aug; 86(2):211-219. PubMed ID: 32638093
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
Kelly RJ; Thomas A; Rajan A; Chun G; Lopez-Chavez A; Szabo E; Spencer S; Carter CA; Guha U; Khozin S; Poondru S; Van Sant C; Keating A; Steinberg SM; Figg W; Giaccone G
Ann Oncol; 2013 Oct; 24(10):2601-2606. PubMed ID: 23857959
[TBL] [Abstract][Full Text] [Related]
6. Formulation design and evaluation of liposomal sepantronium bromide (YM155), a small-molecule survivin suppressant, based on pharmacokinetic modeling and simulation.
Shakushiro K; Kawano H; Nakata M; Kita A; Maeda A; Watanabe S; Sako K; Oku N
Pharm Res; 2015 Jan; 32(1):238-47. PubMed ID: 25033765
[TBL] [Abstract][Full Text] [Related]
7. Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [
Mitsuoka K; Kita A; Murakami Y; Shirasuna K; Noda A; Yamanaka K; Kaneko N; Miyoshi S
Nucl Med Biol; 2018; 64-65():41-46. PubMed ID: 30041149
[TBL] [Abstract][Full Text] [Related]
8. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
Nakahara T; Yamanaka K; Hatakeyama S; Kita A; Takeuchi M; Kinoyama I; Matsuhisa A; Nakano K; Shishido T; Koutoku H; Sasamata M
Anticancer Drugs; 2011 Jun; 22(5):454-62. PubMed ID: 21389848
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells.
Kaneko N; Yamanaka K; Kita A; Tabata K; Akabane T; Mori M
Biol Pharm Bull; 2013; 36(12):1921-7. PubMed ID: 24432379
[TBL] [Abstract][Full Text] [Related]
11. Targeting Taxanes to Castration-Resistant Prostate Cancer Cells by Nanobubbles and Extracorporeal Shock Waves.
Marano F; Rinella L; Argenziano M; Cavalli R; Sassi F; D'Amelio P; Battaglia A; Gontero P; Bosco O; Peluso R; Fortunati N; Frairia R; Catalano MG
PLoS One; 2016; 11(12):e0168553. PubMed ID: 28002459
[TBL] [Abstract][Full Text] [Related]
12. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.
Iwasa T; Okamoto I; Takezawa K; Yamanaka K; Nakahara T; Kita A; Koutoku H; Sasamata M; Hatashita E; Yamada Y; Kuwata K; Fukuoka M; Nakagawa K
Br J Cancer; 2010 Jun; 103(1):36-42. PubMed ID: 20517311
[TBL] [Abstract][Full Text] [Related]
13. Suppression of Rotenone-Treated Human Breast Cancer Stem Cell Survival Using Survivin Inhibitor YM155 is Associated to Oxidative Stress Modulation.
Syahrani RA; Yunita E; Wanandi SI
Asian Pac J Cancer Prev; 2020 Sep; 21(9):2631-2637. PubMed ID: 32986362
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-
Wu M; Wang Y; Wang Y; Zhang M; Luo Y; Tang J; Wang Z; Wang D; Hao L; Wang Z
Int J Nanomedicine; 2017; 12():5313-5330. PubMed ID: 28794625
[TBL] [Abstract][Full Text] [Related]
15. YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction.
Dai CH; Shu Y; Chen P; Wu JN; Zhu LH; Yuan RX; Long WG; Zhu YM; Li J
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3786-3798. PubMed ID: 30315932
[TBL] [Abstract][Full Text] [Related]
16. Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.
Kaneko N; Mitsuoka K; Amino N; Yamanaka K; Kita A; Mori M; Miyoshi S; Kuromitsu S
Clin Cancer Res; 2014 Apr; 20(7):1814-22. PubMed ID: 24486595
[TBL] [Abstract][Full Text] [Related]
17. Survivin suppression heightens BZML-induced mitotic catastrophe to overcome multidrug resistance by removing therapy-induced senescent A549/Taxol cells.
Bai Z; Zhou Y; Ye X; Li Y; Peng Y; Guan Q; Zhang W; Ma L
Biochim Biophys Acta Mol Cell Res; 2022 Feb; 1869(2):119174. PubMed ID: 34808206
[TBL] [Abstract][Full Text] [Related]
18. YM155, a small molecule inhibitor of survivin expression, sensitizes cancer cells to hypericin-mediated photodynamic therapy.
Gyurászová K; Mikeš J; Halaburková A; Jendželovský R; Fedoročko P
Photochem Photobiol Sci; 2016 Jun; 15(6):812-21. PubMed ID: 27241169
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Survivin with YM155 Induces Durable Tumor Response in Anaplastic Thyroid Cancer.
Mehta A; Zhang L; Boufraqech M; Liu-Chittenden Y; Zhang Y; Patel D; Davis S; Rosenberg A; Ylaya K; Aufforth R; Li Z; Shen M; Kebebew E
Clin Cancer Res; 2015 Sep; 21(18):4123-32. PubMed ID: 25944801
[TBL] [Abstract][Full Text] [Related]
20. The small molecule survivin inhibitor YM155 may be an effective treatment modality for colon cancer through increasing apoptosis.
Li WL; Lee MR; Cho MY
Biochem Biophys Res Commun; 2016 Mar; 471(2):309-14. PubMed ID: 26855135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
